Wall Street is positive on Corvus Pharmaceuticals Inc (CRVS). On average, analysts give Corvus Pharmaceuticals Inc a Strong Buy rating. The average price target is $9.25, which means analysts expect the stock to gain by 172.06% over the next twelve months.
That average ranking earns Corvus Pharmaceuticals Inc an Analyst Rating of 60, which is better than 60% of stocks based on data compiled by InvestorsObserver.
Why are Analyst Ratings Important?
Analytical research by professionals can be extremely useful when making investment decisions in the stock market. Analysts are able to observe industries in detail and learn how geographical impacts can affect a company's balance sheet. This information allows investors to make decisions ahead of the curve.
InvestorsObserver combines the ratings from these analysts and proceeds to percentile rank them. This grants you the ability to compare stocks in a comprehensive fashion as oppossed to a standard buy/hold/sell rating.
What's Happening With Corvus Pharmaceuticals Inc Stock Today?
Corvus Pharmaceuticals Inc (CRVS) stock is lower by -2.36% while the S&P 500 is higher by 2.33% as of 1:36 PM on Monday, Mar 1. CRVS is down -$0.08 from the previous closing price of $3.48 on volume of 931,611 shares. Over the past year the S&P 500 has gained 26.20% while CRVS is higher by 4.94%. CRVS lost -$1.51 per share the over the last 12 months.